ABCL vs. MDGL, ALPN, NUVL, ALKS, PRGO, CRNX, AXSM, CORT, HCM, and RARE
Should you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), Perrigo (PRGO), Crinetics Pharmaceuticals (CRNX), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), HUTCHMED (HCM), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical preparations" industry.
AbCellera Biologics (NASDAQ:ABCL) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than AbCellera Biologics. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 5 mentions for AbCellera Biologics. Madrigal Pharmaceuticals' average media sentiment score of 1.18 beat AbCellera Biologics' score of 0.87 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.
AbCellera Biologics has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -410.47%. AbCellera Biologics' return on equity of -12.61% beat Madrigal Pharmaceuticals' return on equity.
AbCellera Biologics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 32.5% of AbCellera Biologics shares are owned by insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
AbCellera Biologics presently has a consensus target price of $16.17, suggesting a potential upside of 312.41%. Madrigal Pharmaceuticals has a consensus target price of $345.09, suggesting a potential upside of 46.13%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities analysts plainly believe AbCellera Biologics is more favorable than Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals received 399 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 77.27% of users gave AbCellera Biologics an outperform vote while only 68.60% of users gave Madrigal Pharmaceuticals an outperform vote.
Summary
AbCellera Biologics beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get AbCellera Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AbCellera Biologics Competitors List
Related Companies and Tools
